Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Discovering Human Tumor-Antigens
The first human cancer antigen was discovered by an LICR team that included Drs. Thierry Boon and Etienne de Plaen (pictured) from the LICR Brussels Branch, and LICR Affiliate Dr. Alexander Knuth. The discovery of human cancer antigens allowed the development of vaccines, which target these antigens, to treat cancer. More »
News
Providing another tool to help to understand gene regulation on a global scale, a nationwide research team has identified and mapped 55,000 enhancers, short regions of DNA that act to enhance or boost the expression of genes. The map, which will be published March 18 in the advance on-line edition of the journal Nature, will help scientists understand how cells control expression of genes specific to their particular cell type.
February 26, 2009
New Tool for Genome-Wide Association Studies
Modern genotyping technologies offer new opportunities to explore how genes influence health and disease, but also present the challenge of analyzing huge amounts of genetic and clinical data. With this in mind, investigators at the Lausanne Branch of the international Ludwig Institute for Cancer Research (LICR), the Swiss Institute of Bioinformatics (SIB) and the University Hospital of Lausanne have developed AssociationViewer, a computational tool that displays genetic differences between individuals on a large scale.